Ario Pharma Ltd is developing new therapeutics for the treatment of respiratory indications.
The Company is currently evaluating the anti-tussive properties of its lead asset XEN-D0501, a best-in-class oral TRPV1 inhibitor, with Phase 2 clinical trials currently ongoing for chronic idiopathic cough (CIC) and COPD cough.
A TRPA1 lead optimisation project is also underway, focusing on asthma.
Please contact us to arrange a meeting at one of the events we are attending.
Ario Pharma Acquires PharmEste’s TRPA1 Research Assets